Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Service de Biochimie Médicale et Biologie Moléculaire, |
RCV001172425 | SCV001335484 | pathogenic | Fraser syndrome 1 | 2018-09-14 | criteria provided, single submitter | clinical testing | This variant in homozygous state or compound heterozygous state induced Fraser syndrome phenotype |
Invitae | RCV003688920 | SCV004450733 | likely pathogenic | not provided | 2023-03-29 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the C-terminus of the FRAS1 protein. Other variant(s) that disrupt this region (p.Arg3849Aspfs*8, p.Asn3967Glufs*2) have been observed in individuals with FRAS1-related conditions (PMID: 18671281, 31923588, 32488952). This suggests that this may be a clinically significant region of the protein. ClinVar contains an entry for this variant (Variation ID: 916656). This variant has not been reported in the literature in individuals affected with FRAS1-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change creates a premature translational stop signal (p.Gln3825*) in the FRAS1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 188 amino acid(s) of the FRAS1 protein. |